The DOI matches its Crossref record.
Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases
Abstract
In 1982, when the Orphan Drug Act was passed as an amendment to the Federal Food, Drug, and Cosmetic Act,1 few suspected the extent to which this law would alleviate the plight of patients with rare diseases. The law defines an orphan drug as one with efficacy against a disease affecting fewer than 200,000 people in the United States or one that scientists and economists at the Food and Drug Administration (FDA) determine will not be profitable for seven years after FDA approval.2 In the 24 years since this law was passed, 282 such drugs and biologic products, providing treatment . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Why rare diseases are an important medical and social issue
Schieppati, A., Henter, J.-I., Daina, E., & Aperia, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60872-7 · Cited by 619
Richter, T., Nestler-Parr, S., Babela, R., Khan, Z. M., Tesoro, T., Molsen, E., & Hughes, D. A. (2015) · Value in Health · doi:10.1016/j.jval.2015.05.008 · Cited by 590
Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M., & Fleury, M. E. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy221 · Cited by 570
The importance of new companies for drug discovery: origins of a decade of new drugs
Kneller, R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3251 · Cited by 344
Assessing the economic challenges posed by orphan drugs
Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462307051550 · Cited by 279
Rare diseases, orphan drugs and their regulation: questions and misconceptions
Tambuyzer, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3275 · Cited by 182
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
Braun, M. M., Farag-El-Massah, S., Xu, K., & Coté, T. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3160 · Cited by 148
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
Metadata
- Authors
- Haffner, M. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-02
- Volume
- 354
- Issue
- 5
- Pages
- 445-447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2035802792
- Cited by
- 162
- References
- 0
- FWCI
- 23.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.